Amylin Pharmaceuticals ($AMLN) is involved in intense buyout negotiations with at least a pair of Big Pharma suitors, according to Bloomberg. The business news service once again quotes insiders, this time saying that Sanofi ($SNY) and Merck ($MRK) have each offered $25 a share, or $4 billion, for the diabetes drug company. And Takeda Pharmaceutical Industries and Bristol-Myers Squibb ($BMY), which reportedly got the ball rolling, are preparing new offers as several others ponder getting into the bidding war. Nothing has ever been publicly confirmed about this process. But if nothing else, Bloomberg is spurring a bidding war with its regular stream of insider accounts--which is exactly what Amylin wants. Story